Related Experiment Videos
Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium
S M Troy1, V D Parker, D R Hicks
1Clinical Research and Development, Wyeth-Ayerst Research, Philadelphia, Pennsylvania 19101-1245, USA.
Journal of Clinical Pharmacology
|February 1, 1996
Summary
Coadministration of venlafaxine and lithium does not result in clinically significant pharmacokinetic interactions. Lithium slightly impacts venlafaxine renal clearance, but does not alter its overall elimination, ensuring safe co-prescription.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Interactions
Background:
- Venlafaxine is a novel antidepressant.
- Concomitant use of lithium and antidepressants is common.
- Assessing pharmacokinetic interactions is crucial for patient safety.
Purpose of the Study:
- To evaluate the effect of venlafaxine on lithium pharmacokinetics.
- To assess the impact of lithium on venlafaxine and O-desmethylvenlafaxine disposition.
- To determine the clinical significance of potential drug interactions.
Main Methods:
- Open-label study design.
- Multiple-dose venlafaxine administration.
- Single-dose lithium administration and vice versa.
- Pharmacokinetic parameter analysis.
Main Results:
- Lithium reduced venlafaxine renal clearance but did not affect total clearance.
- Lithium did not alter O-desmethylvenlafaxine elimination.
- Venlafaxine slightly increased lithium absorption rate but not extent.
- Venlafaxine did not affect lithium total clearance or volume of distribution.
Conclusions:
- No clinically significant pharmacokinetic interactions between venlafaxine and lithium were observed.
- Co-administration of these drugs is likely safe from a pharmacokinetic perspective.
- Further clinical studies may be warranted to confirm long-term safety.